Schwartz B L, Hashtroudi S, Herting R L, Schwartz P, Deutsch S I
Psychiatry Service, Veterans Affairs Medical Center, Washington, DC 20422, USA.
Neurology. 1996 Feb;46(2):420-4. doi: 10.1212/wnl.46.2.420.
We tested the ability of d-cycloserine, a partial glycine agonist acting at the N-methyl-D-aspartate (NMDA) receptor complex, to improve implicit memory in Alzheimer patients in a parallel-group, placebo-controlled, double-blind study. One-hundred eight patients with probable Alzheimer's disease of mild to moderate severity received d-cycloserine (5, 15, or 50 mg) or placebo twice daily for 10 weeks. We then evaluated their ability to identify perceptually degraded words, some of which were repeated over multiple trials across 3 days. Implicit memory performance of words repeated across trials was significantly enhanced for the patients who received 15 mg d-cycloserine compared with those who received placebo. These findings support development of NMDA receptor-mediated glutamatergic interventions for the treatment of Alzheimer-related memory disorders.
我们在一项平行组、安慰剂对照、双盲研究中，测试了作用于N-甲基-D-天冬氨酸（NMDA）受体复合物的部分甘氨酸激动剂d-环丝氨酸改善阿尔茨海默病患者内隐记忆的能力。108例轻度至中度可能患有阿尔茨海默病的患者每天两次接受d-环丝氨酸（5、15或50毫克）或安慰剂治疗，持续10周。然后我们评估了他们识别感知退化单词的能力，其中一些单词在3天内的多次试验中重复出现。与接受安慰剂的患者相比，接受15毫克d-环丝氨酸的患者在各试验中重复单词的内隐记忆表现显著增强。这些发现支持开发NMDA受体介导的谷氨酸能干预措施来治疗阿尔茨海默病相关的记忆障碍。
